Mitsubishi Tanabe Unit Plans 40% Growth In Generics Portfolio In 10 Years
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharma Group's generics subsidiary plans a 40% increase in its portfolio within the next 10 years to take advantage of what is expected to be an expanded market for the drugs.